Tissue and blood biomarkers in lung cancer: a review

MJ Duffy, K O'Byrne - Advances in clinical chemistry, 2018 - Elsevier
Lung cancer is the most common cause of cancer-related death, worldwide. Historically,
lung cancer has been divided into two main histological types: small cell and nonsmall cell …

The economic case for precision medicine

SP Gavan, AJ Thompson, K Payne - Expert review of precision …, 2018 - Taylor & Francis
Introduction: The advancement of precision medicine into routine clinical practice has been
highlighted as an agenda for national and international health care policy. A principle barrier …

Non–small cell lung cancer, version 5.2017, NCCN clinical practice guidelines in oncology

DS Ettinger, DE Wood, DL Aisner, W Akerley… - Journal of the National …, 2017 - jnccn.org
This selection from the NCCN Guidelines for Non–Small Cell Lung Cancer (NSCLC)
focuses on targeted therapies and immunotherapies for metastatic NSCLC, because …

First‐line atezolizumab in addition to bevacizumab plus chemotherapy for metastatic, nonsquamous non–small cell lung cancer: A United States–based cost …

XM Wan, X Luo, CQ Tan, XH Zeng, YC Zhang… - Cancer, 2019 - Wiley Online Library
Background The IMpower150 trial found that adding atezolizumab to the combination of
bevacizumab and chemotherapy improved survival for patients with metastatic …

Circulating HMGB1 and RAGE as clinical biomarkers in malignant and autoimmune diseases

C Pilzweger, S Holdenrieder - Diagnostics, 2015 - mdpi.com
High molecular group box 1 (HMGB1) is a highly conserved member of the HMG-box-family;
abundantly expressed in almost all human cells and released in apoptosis; necrosis or by …

Facile sonochemically-assisted bioengineering of titanium dioxide nanoparticles and deciphering their potential in treating breast and lung cancers: biological …

NK Sedky, NK Mahdy, NM Abdel-Kader… - RSC …, 2024 - pubs.rsc.org
Combining sonochemistry with phytochemistry is a modern trend in the biosynthesis of
metallic nanoparticles (NPs), which contributes to the sustainability of chemical processes …

Systematic review of health state utility values in metastatic non-small cell lung cancer with a focus on previously treated patients

N Paracha, A Abdulla, KS MacGilchrist - Health and quality of life …, 2018 - Springer
Background Health state utility values (HSUVs) are an important input to economic
evaluations and the choice of HSUV can affect the estimate of relative cost-effectiveness …

Cost-effectiveness of lung cancer screening and treatment methods: a systematic review of systematic reviews

FE Azar, S Azami-Aghdash, F Pournaghi-Azar… - BMC health services …, 2017 - Springer
Background Due to extensive literature in the field of lung cancer and their heterogeneous
results, the aim of this study was to systematically review of systematic reviews studies which …

[HTML][HTML] Pharmacogenetic studies with oral anticoagulants. Genome-wide association studies in vitamin K antagonist and direct oral anticoagulants

N Cullell, C Carrera, E Muiño, N Torres, J Krupinski… - Oncotarget, 2018 - ncbi.nlm.nih.gov
Oral anticoagulants (OAs) are the recommended drugs to prevent cardiovascular events and
recurrence in patients with atrial fibrillation (AF) and cardioembolic stroke. We conducted a …

Cost-effectiveness analysis comparing companion diagnostic tests for EGFR, ALK, and ROS1 versus next-generation sequencing (NGS) in advanced …

L Schluckebier, R Caetano, OU Garay, GT Montenegro… - BMC cancer, 2020 - Springer
Background The treatment of choice for advanced non–small cell lung cancer is selected
according to the presence of specific alterations. Patients should undergo molecular testing …